



Dedicated To Life

May 13, 2022

**BSE Limited**

1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.: Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated May 13, 2022 titled "**Zydus announces the launch of Bemdac**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

(Formerly known as CADILA HEALTHCARE LIMITED)

A handwritten signature in black ink, appearing to read "Dhaval N. Soni". The signature is written in a cursive style and is positioned above a horizontal line.

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



## Zydus announces the launch of Bemdac<sup>®</sup> for the first time in India to treat uncontrolled LDL-Cholesterol

- Bemdac<sup>®</sup> (Bempedoic acid), a new class of drug that treats uncontrolled LDL-Cholesterol, despite the use of a maximum tolerated dose of statins.

Ahmedabad, India, 13 May 2022

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven global lifesciences company announces the launch of Bemdac<sup>®</sup> (Bempedoic acid), a new class of drug for the first time in India. The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management.

LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases. According to studies, 8 out of 10 Indians are dyslipidemic<sup>1</sup> and 112 million adults suffer from high levels of LDL-c<sup>2</sup>. 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c<sup>3</sup>. Besides this, 5.4 million Indians are found to be intolerant to statin therapy<sup>4,5</sup>. Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need which Bemdac<sup>®</sup> addresses.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences said “With Bemdac<sup>®</sup> we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c. Bemdac<sup>®</sup> is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol. Our mission is to empower patients with a better quality of life through effective disease management and with Bemdac<sup>®</sup> we have taken a great leap ahead in this endeavour.”

Zydus has several leading brands to address cardiac care and dyslipidemia. This includes Atorva<sup>®</sup>, Clopitorva<sup>®</sup>, Zyrova<sup>®</sup> and Pivasta<sup>®</sup>. The company’s brand Atorva<sup>®</sup> is a leader in the Atorvastatin market with a market share of 18.4%. The brand is also ranked second in terms of market share in the Rs. 2162 crore statin segment (AWACS Report Feb’22).



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : ‘Zydus Corporate Park’,  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : www.zyduslife.com  
CIN : L24230GJ1995PLC025878

**References:**

1. Joshi SR et.al., PLoS One, 2014 May 9;9(5):e96808 (ICMR-INDIAB study)
2. Gupta R et.al., Indian Heart Journal 2014, 69, 382-392
3. Ray KK et.al Eur J Prev Cardiol. 2021, 28(11),1279-1289
4. Wander GS et al. Lipids Health Dis. 2017 Jul 3;16(1):130
5. AWACS Feb'22 Statin Unit Ramp Up Analysis

**About Zydus**

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit [www.zyduslife.com](http://www.zyduslife.com).

\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878